The IL‐1 receptor antagonist IL‐1RA is a registered drug, which broadly affects the diverse clinical effects of IL‐1 hyper‐activation and IL‐1RA treatment has been shown to attenuate the symptoms in patients with bladder pain syndrome.46 Here, IL1A is linked to interstitial cystitis.